EAACI is an association of clinicians, researchers and allied health professionals, dedicated to improving the health of people affected by allergic diseases. With more than 9,000 members from 121 countries and 52 National Societies, EAACI is the primary source of expertise in Europe for all aspects of allergy.
Inception of the idea of closer collaboration in the field of allergy at the European level during the 1st European Congress on Allergy, Paris (31 May - 1 June)

The European Academy of Allergy is established in Florence

Constitution and By-Laws are registered in Utrecht

The Lexicon Allergologicum is published with the support of the Academy

The Academy changes its name to “European Academy of Allergy and Clinical Immunology”

Audiovisual Commission is appointed - Chair: Prof. C. Molina

EAACI members reach 1,000

“Allergy” becomes the official journal of the Academy, bearing the additional subtitle “European Journal of Allergy and Clinical Immunology”

The Academy revises its By-Laws; Membership is opened up to Corporate Societies

1st Allergy School takes place in El Escorial, Spain; EAACI’s first website is launched

EAACI Sections are established: Asthma, Pediatrics, Dermatology (Allergic Skin Diseases), ENT, Immunology

Creation of the Junior Members and Affiliates membership category

Creation of the Interest Groups at the Brussels Congress

EAACI CME Accreditation Council is created

Establishment of the Ethics Committee

Creation of the position of Scientific Programme Coordinator - 1st SPC: Sergio Romagnani

GA²LEN is established in the EAACI office in Brussels and sponsored by the EU FP6

EAACI presents the EAACI Awards for the first time

EAACI Headquarters is established in Zurich

Biggest world allergy congress ever, with 7,989 registered delegates, takes place in London

Launch of the European Declaration on Immunotherapy

Launch of the EAACI journal Clinical and Translational Allergy

Rollout of EAACI Campaign for Allergen Immunotherapy

Launch of the Food Allergy & Anaphylaxis guidelines

Launch of the Global Atlas of Asthma

EAACI members reach 8,000

Rollout of Food, Allergy & Anaphylaxis Campaign

Opened EU liaison office

Rollout of EAACI Allergy Awareness Campaign

Launch of the Global Atlas of Allergy

Established EU Parliament IG on Allergy and Asthma

Launch of the Global Atlas of ENT

EAACI Members reach 9,000

60 years of EAACI - Dedicated to allergy science, committed to your health
The European Academy of Allergy and Clinical Immunology (EAACI) is a non-profit organisation active in the field of allergic and immunologic diseases such as asthma, rhinitis, eczema, occupational allergy, food and drug allergy and anaphylaxis.

Our mission, aims and objectives

Allergic and immunologic diseases currently represent chronic or life threatening conditions and are a cause of worldwide concern. Since its establishment in 1956 in Florence, EAACI has a mission to provide the most efficient platform for scientific communication and education in the field of allergy and immunology, ultimately striving to ease the suffering of patients who have these diseases.

In pursuit of our mission, we seek to accomplish the following aims:

- Promote basic and clinical research
- Collect, assess and disseminate scientific information
- Function as a scientific reference body for other scientific, health and political organisations
- Encourage and provide training and continuous education
- Collaborate with patients and lay organisations and promote good patient care

A thriving organisation

The desire to improve the health of people affected by allergic diseases and to serve as the primary source of expertise in Europe for all aspects of allergy runs through all EAACI activities, from our varied editorial programme to our rich agenda of world-class meetings. Having consistently striven to adhere to the above aims, EAACI has grown to become the largest medical association in Europe in the field of allergy and clinical immunology. Its growing membership currently includes more than 9,000 members from 121 countries, representing academicians, clinicians and allied health professionals. In addition, EAACI includes 52 National Allergy Societies as members.

“It is an honour for me to serve as president of EAACI. The organisation has grown rapidly in past years because we are committed to providing our members excellent science and education as well as promoting the best healthcare for allergy patients. I believe we can have an even greater impact in the future if we also allocate resources behind the advocacy, recognition, and prioritisation of allergy as a specialty as well as behind innovative trends like high quality guidelines for clinical practice, precision medicine, and health economics for allergic diseases and asthma.”

Prof. Antonella Muraro
EAACI President
Head Food Allergy Referral Centre
Veneto Region
Department of Women and Child Health
Padua General University Hospital

“Allergy is one of the major diseases of our times. EAACI, the European reference for research, education and advocacy on allergy, has grown into the International leader in the field. There is a strong will to continue improving the quality of life of allergic patients, demonstrating to society the importance of effectively managing allergy and asthma.”

Prof. Nikos Papadopoulos
EAACI Past-President
Professor in Allergology - Pediatric Allergology,
Head, Allergy Dept, 2nd Pediatric Clinic,
University of Athens

“Being on the EAACI Executive Committee for the last 10 years, and serving as the President from 2011 - 2013, has for me been one of the most exciting times of my life. I would sincerely like to thank everyone who has worked with such enthusiasm and hard work to establish our Academy on such solid grounds. The best thing we did in our Academy was to focus and invest on better education and career development for our next generation of scientists and clinicians, namely our Junior Members.”

Prof. Cezmi Akdis
EAACI Past-President
Director of Swiss Institute of Allergy and Asthma Research (SIAF) and Christine Kühne - Center for Allergy Research and Education (CK-CARE)
EAACI’s structure is derived from its Constitution and By-Laws which were registered in Utrecht in 1957 and last amended in 2009 and 2015. The governing body of EAACI is its General Assembly representing all EAACI members. The General Assembly elects, from among individual members of the Academy, the Executive Committee which acts as the main administrative body of the Academy. The Executive Committee institutes specialised Committees to handle specific aspects of the Academy’s work. Parallel to the Committees, the Sections, Interest Groups and the Junior Members Assembly are important structural units that facilitate Academy functions and activities.

Continuing Medical Education (CME) Committee
Oversees the content and delivery of CME accreditation, as well as advising on and approving the content of educational programmes.

Ethics Committee
Ensures high ethical standards in all areas of the EAAACI activity.

Exam Committee
Coordinates the EAACI/UEMS knowledge examination.

Executive Committee
Comprises the Board of Officers, six members-at-large, the Chairpersons of the EAACI Sections, two IG representatives, and the JM Chairperson.

Interest Groups (IG)
Provide a focus for scientists and clinicians interested in particular aspects of allergic diseases.

Junior Members Working Group
Coordinates the activities for Junior Members (JMs) and provides advice to the Executive Committee.

National Allergy Societies (NAS) Committee
Brings together the NAS and EAACI representatives, and the International Societies Council Chairperson in order to facilitate constant communication and improve the collaboration on various projects.

Patient Organisations Committee
Brings together the most influential Patient Organisations from all over the world and facilitates communication between stakeholders involved in the field of allergy (clinicians and researchers, patients’ organisations, industry, regulatory bodies).

Scientific Programme Committee
Maintains high scientific standards and ensures continuity and harmonisation of the EAACI Congresses.

Sections
Facilitate information exchange and collaboration between specialists and scientists both within and outside the EAACI.

Specialty Committee
Co-ordinates activities in Europe in the areas of undergraduate and postgraduate teaching in allergy and clinical immunology and also deals with recognition of the specialty, free circulation of specialists within Europe.

Web Committee
Develops strategies for online communication development.

“One of the advantages of reaching 100 years, is that from the very small beginnings of EAACI and having attended 30 EAACI Congresses, I can say that we are the world’s leading allergy society. The official journal Allergy, and the position papers prepared by the Task Forces, indicate that EAACI excels in the development of communication of all matters allergic in the field of clinical research and education.”

Dr William Frankland
EAACI Past-President
Founder Member and Past-President of the International Association of Aerobiology

“EAACI represents a platform for science and friendship, a meeting point for education, a guidance to care of allergic patients, and a promise for the future of young scientists and clinicians.”

Prof. Roy Gerth van Wijk
EAACI Past-President
EAACI Specialty Committee Chairperson

INTEREST GROUPS (IG)
- IG on Aerobiology & Pollution
- IG on Allergy, Asthma & Sports
- IG on Allergy Diagnosis
- IG on Allied Health
- IG on Biologicals
- IG on Comparative and Veterinary Allergology
- IG on Drug Allergy
- IG on Eosinophilic Esophagitis
- IG on Epidemiology
- IG on Food Allergy
- IG on Immunotherapy
- IG on Infection & Allergy
- IG on Insect Venom Hypersensitivity
- IG on Occupational Allergy
- IG on Ocular Allergy
- IG on OMICS and Systems Medicine
- IG on Primary Care
- IG on Primary Immunodeficiency

SECTIONS
- Asthma
- Dermatology
- ENT
- Immunology
- Pediatrics
ORGANISATION OF EAACI

GENERAL ASSEMBLY

Members | Junior Members | National Societies

Asthma Section
Dermatology Section
ENT Section
Immunology Section
Pediatrics Section

ORGANISATION OF EAACI

MEMBERS' GROUPS

Continuing Medical Education
Ethics
Exam
National Allergy Societies
Patients Organisations
Scientific Programme
Specialty
Web

COMMITTEES

Executive

Board of Officers
- President
- Secretary General
- Treasurer
- Vice-President Congresses
- Vice-President Education & Specialty
- Vice-President Communications & Membership
- Past-President
- Executive Director (non voting)

Members at Large (6)
Section Chairpersons (5)
Interest Group Representatives (2)
Junior Members Chairperson
Adjunct Members - Committee Chairs (non-voting)

HEADQUARTERS

IG=Interest Groups
A public health threat of pandemic scope

It is currently estimated that up to 30% of Europeans suffer from allergic rhinitis or conjunctivitis, while up to 20% suffer from asthma and 15% from allergic skin conditions, with an increasing prevalence in many regions. The burden peaks at the 20-40 year old age group with clinical symptoms of rhinitis reaching 45%. The worldwide numbers are equally alarming. Almost half a billion people suffer from rhinitis and approximately 300 million from asthma.4 Food allergies are also becoming more frequent and severe. Occupational allergies, drug allergies and allergies to the venom of stinging insects (sometimes fatal) add further complexity and concerns. Finally, new types of allergic diseases and allergies against previously non-allergenic substances are being increasingly reported. Taking into account the upwards trends shown by epidemiological studies, EAACI predicts that in less than 15 years more than half of the European population will suffer from some type of allergy.

What is allergy?

Allergy is an exaggerated response of the human defence system against generally harmless substances.

Facts about allergies

- Allergies are the most frequent chronic diseases in children and young adults.
- Allergies usually start in childhood and persist for many years, often for life. However, allergies can develop at any age.
- Patients with one allergic disease have a high risk of developing more allergies.
- In children, very often one allergic disease follows another (allergic march). Atopic eczema appears first, affecting more than 10% of babies in Europe.
- Allergies run in families but most new cases appear in people without a previous family history of allergy.
- Asthma and allergic rhinitis very frequently co-exist in the same person; they are together called respiratory allergy.

The mechanisms of allergy

An ‘allergen’, e.g. pollen, is wrongly recognised by the immune system, which produces IgE antibodies against it (sensitisation phase). IgE sits on top of ‘mast cells’ that contain many highly active molecules (mediators). When the allergen re-enters the body, it is recognised by the IgE on top of the mast cells, making them ‘explode’, releasing their mediators and resulting in the symptoms of allergy.

**First exposure**

You build antibodies that will recognise the allergen in the future.

**Next exposure**

Your antibodies recognise the allergen and trigger an allergic response.
Allergy’s multiple impact

The impact of allergies is detrimental both to individuals and society as a whole. Patients face a relentless impairment to their quality of life, sleep, mood, performance at work or school and overall personal development. In addition, society at large confronts increasing associated direct and indirect costs of a scale that will soon become impossible to contend with. Performance deficits, loss of productivity and absenteeism linked to allergy suffering have a major effect on macroeconomics, while direct medical costs, including hospitalisation, drain national economies of much needed resources. With a current estimate of more than 150 million patients and a prediction of more than 250 million patients in Europe in the next decade, allergies constitute a public health concern of pandemic proportions that requires immediate and concerted action.¹


³The diagnosis and management of rhinitis: an updated practice parameter. Wallace DV, Dykewicz MS, Bernstein DI, et al: Joint Task Force on Practice; American Academy of Allergy; Asthma and Immunology; American College of Allergy; Asthma and Immunology; Joint Council of Allergy, Asthma and Immunology. J Allergy Clin Immunol. 2008 Aug; 122 (2 Suppl): S1-84.


⁵A European Declaration on Immunotherapy. European Academy of Allergy and Clinical Immunology, 2011.
<table>
<thead>
<tr>
<th>Year 1</th>
<th>Year 2</th>
<th>Name</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>1956</td>
<td>1959</td>
<td>U. Serafini</td>
<td>Italy</td>
</tr>
<tr>
<td>1959</td>
<td>1962</td>
<td>D. A. Williams</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>1962</td>
<td>1965</td>
<td>E. Bruun</td>
<td>Denmark</td>
</tr>
<tr>
<td>1965</td>
<td>1968</td>
<td>H. Herxheimer</td>
<td>Germany</td>
</tr>
<tr>
<td>1968</td>
<td>1971</td>
<td>J. Duchaine</td>
<td>Belgium</td>
</tr>
<tr>
<td>1971</td>
<td>1974</td>
<td>S. Kraepelien</td>
<td>Sweden</td>
</tr>
<tr>
<td>1974</td>
<td>1977</td>
<td>J. Charpin</td>
<td>France</td>
</tr>
<tr>
<td>1977</td>
<td>1980</td>
<td>A. W. Frankland</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>1980</td>
<td>1983</td>
<td>J. P. Girard</td>
<td>Switzerland</td>
</tr>
<tr>
<td>1983</td>
<td>1986</td>
<td>C. Molina</td>
<td>France</td>
</tr>
<tr>
<td>1986</td>
<td>1989</td>
<td>M. Debelic</td>
<td>Germany</td>
</tr>
<tr>
<td>1989</td>
<td>1992</td>
<td>A. B. Kay</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>1992</td>
<td>1995</td>
<td>F. B. Michel</td>
<td>France</td>
</tr>
<tr>
<td>1998</td>
<td>2001</td>
<td>S. Bonini</td>
<td>Italy</td>
</tr>
<tr>
<td>2001</td>
<td>2003</td>
<td>P. van Cauwenberge</td>
<td>Belgium</td>
</tr>
<tr>
<td>2003</td>
<td>2005</td>
<td>U. Wahn</td>
<td>Germany</td>
</tr>
<tr>
<td>2005</td>
<td>2007</td>
<td>A. Frew</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>2007</td>
<td>2009</td>
<td>R. Gerth van Wijk</td>
<td>The Netherlands</td>
</tr>
<tr>
<td>2009</td>
<td>2011</td>
<td>J. Lötvall</td>
<td>Sweden</td>
</tr>
<tr>
<td>2011</td>
<td>2013</td>
<td>C. A. Akdis</td>
<td>Turkey, Switzerland</td>
</tr>
<tr>
<td>2013</td>
<td>2015</td>
<td>N. G. Papadopoulos</td>
<td>Greece</td>
</tr>
<tr>
<td>2015</td>
<td>2017</td>
<td>A. Muraro</td>
<td>Italy</td>
</tr>
</tbody>
</table>
FOSTERING SCIENCE THROUGH DEDICATED PLATFORMS

Through a wide range of well-attended scientific events, EAACI provides an efficient and highly respected avenue for communication and knowledge exchange in the field of allergy and immunology. It also builds links between stakeholders, pushes back scientific frontiers and raises the standards for professionalism, networking, dedication and innovation. EAACI events, including its annual Congress, Focused Meetings, and a number of ad hoc meetings, engage world-renowned experts, promising new members, researchers and practitioners, as well as specialists and generalists in a productive exchange that advances knowledge in the field.

EAACI Congress

EAACI’s flagship event is its Annual Congress, allergy’s premier scientific event. The Congress represents a dedicated platform for dialogue and knowledge dissemination. It brings together the world of allergy, asthma and immunology. Here, all stakeholders discuss and impart good science as well as the latest insights and breakthroughs in the field.

The EAACI Annual Congress features extensive multi-day scientific programmes, with up to 8,000 international delegates. The EAACI Congresses have developed into the largest global congresses in the world by number of participants and the total number of submitted abstracts in the field of allergy, asthma and clinical immunology. The Congresses provide opportunities for sharing ideas, knowledge and best clinical practice, on topics like:

- Allergic Rhinitis
- Allergen Immunotherapy
- Allergy Diagnosis
- Anaphylaxis
- Asthma
- Basic Immunology
- Biologicals and Immune Modulators
- Drug Hypersensitivity
- Food Allergy
- Immune Deficiencies
- Molecular Allergology
- Occupational Allergy
- Pediatric Allergy
- Skin Allergy

CONGRESS ATTENDANCE EVOLUTION

![Congress Attendance Evolution Chart]

- The number of attendees has seen a significant increase over the years, with the peak attendance reaching 8,000 delegates in 2015.
- The chart shows a steady growth trend from 2001 to 2015, demonstrating the increasing popularity and international reach of the EAACI Congresses.

This graphic illustrates the evolution of Congress attendance over the years, reflecting the growing importance and influence of the EAACI Annual Congress in the field of allergy and immunology.
Focused Meetings

EAACI organises several smaller meetings called Focused Meetings. These meetings provide a forum for discussion and in-depth understanding within targeted medical communities about specific topics, such as:

Drug Allergy
DHM - Drug Hypersensitivity Meeting

Experimental Rhinology
SERIN - Symposium on Experimental Rhinology and Immunology of the Nose

Food Allergy
FAAM - Food Allergy and Anaphylaxis Meeting

Molecular Allergology
ISMA - International Symposium on Molecular Allergology

Pediatric Allergy and Asthma
PAAM - Pediatric Allergy and Asthma Meeting

Severe Asthma
ISAF - International Severe Asthma Forum

Skin Allergy
SAM - Skin Allergy Meeting

“Allergic diseases are one of the non-infectious epidemics of the 21st century. Scientific advances in the diagnosis and treatment of these diseases achieved in recent decades are very relevant. For over 20 years I have been attending the EAACI Annual Congress with the same enthusiasm as the first time: to learn, share experiences and plan projects with colleagues around the world. Each year, I carefully prepare my agenda given that this is an event you should not miss.”

Dr. Tomas Chivato
EAACI Executive Committee
Head of the Faculty of Medicine at San Pablo University in Madrid
Past-President of the Spanish Allergology and Clinical Immunology Society

“Whenever I attend the EAACI meetings I feel myself in a family environment. It has been a great pleasure and honour for me to work for the EAACI. During the last 20 years EAACI has been the eye witness to my career development.”

PhD Dr. Mübeccel Akdis
Former Immunology Section Board Member
EAACI Winter School Organiser
Editorial Board member “Allergy” and “Journal of Allergy and Clinical Immunology”

“EAACI sets a very high standard for other allergy and asthma organizations in the excellence of its meetings. Whether one is interested in basic science aspects of allergy and asthma, translational science, or clinical medicine, the programs provide both depth and breadth. Moreover, the EAACI fosters an exceptional level of collegiality. I always enjoy meetings of the EAACI.”

Prof. Dr Stephen J. Galli
President of Collegium Internationale Allergologicum
Chair of the Department of Pathology and Mary Hewitt Loveless, M.D. Professor at Stanford University School of Medicine
EAACI Immunology and Allergy Schools

EAACI holds Immunology and Allergy Schools aimed at training and educating Europe’s motivated young medical specialists in a highly interactive and effective networking environment. The courses cover a variety of different topics, from clinical to basic scientific. They provide up-to-date information on the daily practice of allergists and clinical immunologists and improve participants’ knowledge and skill-base. The impact ultimately improves the overall quality of patient care. Practical work related to each school’s topic is a central aspect of the Immunology and Allergy Schools. These courses are also CME accredited and are arranged in collaboration with the EAACI National Membership Society of the host country.

“Taking a look back at the years that I have been a JM, EAACI has provided me and so many other JMs abundant opportunities to acquire knowledge; in addition to travel grants, reduced registration fees for the Annual Congress, Focused Meetings and Allergy Schools, the Clinical and Research Fellowships, the Mentorship Programme as well as the free online access to EAACI Journals and educational resources.”

Olympia Tsilochristou
EAACI JM Chair

“The EAACI Fellowship gives me the opportunity to work in an international renowned centre and gain new insights in the field of allergy and immunology by discussing data with new colleagues and experts in the field. It will definitely be a boost for my research career!”

Sven Seys, PhD
EAACI Fellowship Winner

“EAACI has given a unique opportunity to integrate allergy practice in the East with the West by combining high quality learning with a vibrant academic atmosphere. I thank, appreciate and respect EAACI for its endeavour to nurture science across the globe.”

Dr Soumya M S.
EAACI Fellowship Winner
**EAACI Fellowships**

Every year, EAACI awards a number of fellowships to JMs interested in increasing their knowledge and skills at Europe’s leading scientific institutions.

### Research Fellowships

The Research Fellowships offer JMs short- to long-term fellowships in a foreign European country. Their purpose is to increase the mobility of young researchers, spread the implementation of new techniques between European laboratories and highlight the work of EAACI JMs.

### Clinical Fellowships

The Clinical Fellowships offer clinicians early in their career the opportunity to train in allergy and clinical immunology next to highly skilled specialists in Europe for a period of three months.

**Continuing Medical Education (CME)**

EAACI is committed to promoting a high level of academic and clinical competence throughout the working life of allergy specialists and to supporting the development of the specialty in Europe. EAACI has implemented a system of Continuing Medical Education (CME) in collaboration with the European Union of Medical Specialists (UEMS) for the accreditation of educational activities in the fields of Allergy and Immunology. It acts as an umbrella organisation for the accreditation of external events, as well as providing CME credits for its own EAACI meetings, ensuring their high scientific value. In this context, credits are also valid in the USA and Canada due to a reciprocal agreement between UEMS, the American Medical Association, and the Royal College of Physicians and Surgeons of Canada.

**Knowledge Examination in Allergy and Clinical Immunology**

The aim of the EAACI/UEMS administered Knowledge Examination is to further raise the standards of allergy and clinical immunology. Its purpose is not to substitute currently existing national examinations regularly held by national bodies but to provide a certification benchmark to further improve the standards of the specialty throughout Europe.

**Primary Care Training in Allergology**

In response to the demand for adequate training in allergology in primary care, EAACI facilitates allergy training during tailored sessions at the EAACI Annual Congress, Postgraduate Courses and at national and international primary care meetings.

**Masterclasses in Allergy and Clinical Immunology**

Masterclasses function as a forum for highly specialised clinicians and researchers in an interactive work environment.
DISSEMINATING KNOWLEDGE

To foster the work in disseminating the science and novel developments in the specialty, EAACI has formed Sections, Interest Groups and Task Forces dealing with specific areas of general interest in allergology. In addition, the Academy seeks to stimulate scientific interest through its editorial activities, which include key journals in the field of allergy, asthma and clinical immunology. It also distills and disseminates the latest and most authoritative findings to members and the wider medical and scientific community.

Sections
Diseases mediated by allergic and immunological mechanisms can affect many different organs and may present problems to a wide variety of physicians in primary and secondary care. In order to strengthen its influence on the work of those clinical specialities where allergy and clinical immunology is of importance, EAACI has established Sections for Asthma, Dermatology, ENT, Immunology, and Pediatrics.
Sections act as a point of contact for relevant specialty societies and non-members, relate to European and National Societies in their relevant areas, promote an understanding of the importance of allergy within those societies, advise the EU on matters of policy within their relevant areas, and promote Europe-wide co-operation in scientific and clinical research.

Interest Groups
EAACI has Interest Groups covering a wide range of topics including Aerobiology & Pollution, Allergy, Asthma & Sports, Allergy Diagnosis, Allied Health, Biologicals, Comparative and Veterinary Allergology, Drug Allergy, Eosinophilic Esophagitis, Epidemiology, Food Allergy, Immunotherapy, Infection & Allergy, Insect Venom Hypersensitivity, Occupational Allergy, Ocular Allergy, OMICS and Systems Medicine, Primary Care, Primary Immunodeficiency.
Interest Groups aim to closely observe developments in their respective fields of study, provide a communication platform for members to share and develop knowledge on the issue at hand, and stimulate inter- and intra-disciplinary collaboration.

Task Forces
Task Forces are action groups bringing together experts from both within the Academy and from related fields to produce position papers on cutting-edge scientific developments and on controversial and topical allergy-related issues. It is a scientific process in which elements of evidence-based medicine meet with social understanding and sensitivity. Most of the position papers are published in the Academy’s official journals and are usually presented at the EAACI Congress.
Position papers may identify necessary actions to mitigate the negative effects of the subject under examination and highlight the need for interventions at a political level.

“EAACI caters for all who are interested in any aspect of allergy and immunology with its Sections (Asthma, Dermatology, ENT, Immunology and Pediatrics) which are represented in the Executive and Programme Committees, and have the opportunity to propose task forces as well as joint sessions with specialist societies. Interest groups, such as Drug Allergy, Immunotherapy, Occupational Allergy, represent areas not adequately covered by the Sections and provide a focus for scientists and clinicians interested in particular aspects of allergic diseases.”

Dr Glenis Scadding
Past EAACI ENT Section Chairperson
Past President of the British Society for Allergy and Clinical Immunology
Journals

- Allergy
- Pediatric Allergy and Immunology
- Clinical and Translational Allergy Journal
  www.ctajournal.com
  Is an open access platform for the publication of original research and reviews in the field of allergy.
- Newsletter
  As the Academy’s voice, the Newsletter is an important source of information aimed at providing a forum for EAACI bodies and members. The Newsletter is published four times a year and reaches all 9000 EAACI members and beyond. It is also distributed at all EAACI meetings and translated into Spanish.

“EAACI is an outstanding scientific and clinical society caring for all aspects of allergic and immune related illnesses worldwide. The education of young fellows and colleagues all around the world is of primordial importance for improving the care of our patients. I am very proud to have received the Daniel Bovet Award for Improving Treatment and Prevention of Allergic Diseases by this prestigious society.”

Prof. Erika von Mutius
Head of the Asthma and Allergy Department of Munich University Children’s Hospital in Munich
Board member of the New England Journal of Medicine and the Journal of Allergy and Clinical Immunology

“I am proud to be an EAACI member since 1973 at the Congress in Pamplona with ca. 200 participants. EAACI has grown spectacularly in quantity and quality; it is our platform to advance excellence in patient care, research and education. It is now reaching out in cooperation with private foundations such as Christine Kühne-Center for Allergy (CK-CARE) to organise common programmes in allergy education.”

Prof. Johannes Ring
Past EAACI Dermatology Section Chairperson
Past-President of the German Allergy Society (DGAKI) and the Collegium Internationale Allergologicum (CIA)
Head of Department of Dermatology and Allergy, Technical University Munich
Allergic diseases are affecting the lives of more than one billion people worldwide. With an epidemic rise during the last 60 years, their prevalence is expected to reach up to 4 billion in 2050. Because of immense numbers of affected individuals, society faces direct and indirect costs with major effects on macroeconomics due to health-care, loss of productivity and absenteeism of patients. Unfortunately, gaps in scientific knowledge on disease mechanisms, prevention, patient care, and social determinants still need to be resolved. To help guide health care professionals with a solid reference tool, EAACI has therefore developed three Global Atlases: the Global Atlas of Asthma, Allergy, and Allergic Rhinitis and Chronic Rhinosinusitis. The Global Atlases are available open-access at www.eaaci.org/resources.

Position Papers

Position papers are the published results gathered by task forces covering relevant, controversial and hot topics. They represent the latest research of specific medical fields within allergology and are published in one of the EAACI Journals. Position Papers can be found open-access on www.eaaci.org/resources.
Food Allergy and Anaphylaxis Guidelines

The EAA CI Food Allergy and Anaphylaxis Guidelines Group has undertaken this unprecedented project from 2012 to 2014. Six task forces have comprehensively reviewed food allergy and anaphylaxis in children, adolescents and adults. The work was carried out by a wide range of health care professionals and scientists along with the involvement of both patient groups and regulators. The activity has been grounded in evidence with the use of comprehensive systematic reviews and, where appropriate, meta-analyses of relevant literature. The EAA CI FAA guidelines were indexed by the prestigious National Guideline Clearinghouse and are now in the implementation phase.

The FAA Guidelines are available for EAACI members at www.eaaci.org/resources.

EAACI Guidelines for AIT

The aim of this EAACI project is to develop comprehensive guidelines for clinical practice on AIT and will embrace all stakeholders (e.g. Clinicians, Immunologists, National Societies Primary care, Regulatory Bodies, Allied Health Representatives, Patient Organizations).

The guidelines will facilitate the implementation of AIT across health professionals while highlighting its benefits at the public and policy makers’ levels and by promoting health economics.

By establishing a methodology working model, the project aims to educate EAACI membership on a shared process for the development of guidelines while establishing a platform that can be used for future initiatives.

ICON – International Consensus On

In light of the increasing burden of allergic diseases, the European Academy of Allergy and Clinical Immunology; the American Academy of Allergy, Asthma & Immunology; the World Allergy Organization; and the American College of Allergy, Asthma & Immunology came together to improve the research of allergic diseases at a global level.

ICONS function as consensus statements available to support medical decisions. They also highlight key messages common to existing guidelines and critically review and comment on differences, thus providing a concise reference.

All ICONs are available open-access at www.eaaci.org/resources.

- ICON on Allergy Immunotherapy
- ICON on Anaphylaxis
- ICON on Chronic Rhinosinusitis
- ICON on Drug Allergy
- ICON on Early Diagnosis of Congenital Immunodeficiencies
- ICON on Eosinophil Disorders
- ICON on Food Allergy
- ICON on Hereditary and Acquired Angioedema
- ICON on Pediatric Allergy
Raising Awareness at a European Level

ADVOCACY MANIFESTO
Tackle the burden of allergy in Europe with evidence-based recommendations

EUROPEAN PARLIAMENT INTEREST GROUP ON ALLERGY AND ASTHMA
Share expertise, align interests and facilitate dialogue to address unmet needs and encourage policy actions

BUILDING STRONG COLLABORATIONS WITH:

- European Federation of Allergy and Airways Diseases Patients’ Associations (EFA) to advocate better patient care
- European Chronic Disease Alliance (ECDA) to raise awareness among policy makers about the surge in chronic diseases
- Alliance for Biomedical Research in Europe (BioMed Alliance) to promote excellence and innovation in European biomedical research
- European Medicines Agency (EMA) to support safe and effective quality interventions for allergic diseases and asthma

2015 EVENTS

8 June, Barcelona
High Level EU Stakeholders Lunch
Strengthen collaboration to curb the growing allergy epidemic

1 July, Brussels
Allergy and Asthma Patients need Clean Air in Europe
Call for better policies to improve air quality to protect the health of patients living with asthma and allergic diseases

14 October, Brussels
Symposium on Precision Medicine in Allergy and Airways Disease
A new challenge for academia, industry, regulatory agencies and patients
EAACI CAMPAIGNS

100 years of allergen immunotherapy

To celebrate the anniversary of allergen immunotherapy in 2011, EAACI developed a number of initiatives.

- SummiT on allergen immunotherapy gathering all stakeholders in the field. The current status of different issues regarding immunotherapy were discussed, assessing certainties and controversies, identifying niches for further research, while established knowledge was set “black on white”. The resulting output, “One hundred years of allergen immunotherapy European Academy of Allergy and Clinical Immunology celebration: review of unanswered questions”, was published in Allergy.

- The “European Declaration on Allergen Immunotherapy”, which was co-signed by national and supranational allergy societies, patient organisations, allergen manufacturers and other third parties, provided a robust statement on the use of immunotherapy, its availability for allergic patients, and the need for resources to fund research.

- The “Leonard Noon Award” was granted to Dr. Alfred William Frankland, an outstanding personality in the field of immunotherapy.

Celebrating 100 Years of Immunotherapy in Allergy 1911-2011

Food Allergy Campaign – Stop Anaphylaxis

The “Stop Anaphylaxis” Food Allergy Campaign went from June 2012 – June 2013. The purpose of the campaign was to raise awareness of the sharp increase of anaphylaxis in children, an allergic reaction that is severe and potentially life threatening. It aimed at educating the public to recognise the symptoms and its triggers and to teach methods of how to react in case of emergency, e.g. by using an adrenaline pen. Campaign collateral includes:

- International Minimum Standards for the Allergic Child at School
- Food Allergy and Anaphylaxis Public Declaration
MEP Written declaration campaign

On October 2013, eleven Members of the European Parliament (MEPs) proposed to draft a Written Declaration on recognising the burden of allergic disease, calling upon the Commission and Member States to recognise the burden of allergic disease and to develop policy tools to combat this illness. At the end of the consultation period, the Declaration was supported by a total of 178 MEPs. The MEPs have made a number of recommendations to help mitigate the impact of allergic diseases, which affect over 150 million Europeans. EU Member States were called upon to implement national programmes, to provide better medical training and to encourage scientific research.

Allergy Awareness Campaign

The Allergy Awareness Campaign aimed to inform Europeans about the burden of allergic diseases and risk factors with an emphasis on an early diagnosis, prevention and appropriate treatments. It also aimed to help patients and their families to better control their allergy and improve their quality of life. The campaign was launched during the EAACI 2014 Congress in Copenhagen, continued in 2014 and 2015 and reached over 14 million Europeans. National Allergy Societies, Pharmacists, Primary Care and Patient Organisations were actively involved in spreading the campaign message. The campaign ran in three waves: Asthma; Food Allergy & Anaphylaxis; and Allergic Rhinitis & Allergen Immunotherapy. The online campaign was complemented with street marketing events: the Awareness Booth in Copenhagen 2014 and the Anaphylaxis School in Barcelona 2015.
The campaign will promote prevention and healthy living and aims to:

- Achieve better funding for research for allergy and asthma prevention
- Increase awareness of allergic diseases and asthma as being preventable and controllable
- Strengthening the allergy speciality

The campaign was launched during the closing ceremony in Barcelona and will run in 2016 with specific events such as:

- Street marketing and educational activities for general public, including specific settings like schools
- Awareness event at the EU Parliament
- Joint events with NAS, pharmacists (PGEU), primary care, patient organisations
- Summit “Present and future of allergy management and research”
EAACI’s broad online presence is an intrinsic part of our communication efforts aimed to reach the world.

- **www.eaaci.org** is the face of the Academy and is one of our most important tools to communicate with members and the allergy community. It provides the latest news and information about Academy events and Schools, Junior Member activities, Grants, Awards, as well as about the work performed by EAACI Sections, Interest Groups and Task Forces.

- **www.eaaci.org/patients** is intended to be an effective source of information and help for allergy patients and non-specialists interested in better understanding the world of allergy.

Of course, EAACI cannot refrain from utilising today’s tools for social interaction. Thus, the Academy has also set up dedicated social media networks, including Facebook, Twitter, LinkedIn and Instagram to keep its community up to date with a constant flow of pertinent information about allergy and Academy activities.

EAACI provides an online platform exclusively for Members. Here, members can access different scientific resources such as presentations, slides and webcasts presented during EAACI events or in the membership directory.
Partners

Strong relationships with international partners are central to EAACI. The Academy has consistently nurtured its partnerships and promoted synergies across the board to optimise patient care. EAACI’s network of partners includes:

AAAAI
The American Academy of Allergy, Asthma & Immunology

ACAAI
The American College of Allergy, Asthma and Immunology

BioMed Alliance
Alliance for Biomedical Research in Europe

ECDA
European Chronic Disease Alliance

EFA
The European Federation of Allergy and Airways Diseases Patients Associations

EMA
European Medicines Agency

ERS
The European Respiratory Society

ERS
The European Rhinologic Society

ESWI
The European Scientific Working Group on Influenza

FOCIS
The Federation of Clinical Immunology Societies

GA²LEN
The Global Allergy and Asthma European Network of Excellence

GARD
The Global Alliance against Chronic Respiratory Diseases

ICAALL
The International Collaboration for Asthma Allergy and Immunology

PGEU
Pharmaceutical Group of the European Union

WAO
The World Allergy Organization

“I have thoroughly enjoyed interacting with colleagues from the EAACI and look forward to future collaborations that will promote research, teaching, and improved clinical care of patients with allergic and immunologic diseases.”

Robert F. Lemanske, Jr., M.D.
President of the American Academy of Allergy, Asthma & Immunology
Professor of Pediatrics and Medicine
Division of Pediatric Allergy, Immunology, and Rheumatology

“I am proud of the long-standing and successful collaboration between patients and allergy health professionals in Europe. Our joint efforts to raise the attention and resources to tackle allergy and asthma are crucial, and we will continue promoting better allergy and asthma prevention and care to improve patients quality of life.”

Christine Roland
European Federation of Allergy and Airways Diseases Patients Associations President

“Personalised medicine is the future. The European Respiratory Society is committed to excellence in science and we are delighted to promote this innovative concept together with other societies such as EAACI.”

Prof. Guy F. Joos
President-Elect of the European Respiratory Society

“As the organisation representing over 400,000 community pharmacists from all over Europe, our collaboration with EAACI on the Allergy Awareness Campaign represents an excellent opportunity for pharmacists to engage with their local communities and raise awareness, provide advice and treatment on allergies and help patients to better manage their medications.”

Jamie Wilkinson
Director of Professional Affairs, Pharmaceutical Group of the European Union
FORGING A COMMUNITY

Above all, EAACI is a community of health care professionals and National Societies with a shared interest: to understand and effectively fight allergy. We cultivate and further expand this unique community that the Academy has helped to create by bringing together and reaching out to all stakeholders. This includes healthcare professionals in allergy and related specialties, patients and international partners.

Membership

The membership of EAACI is rapidly expanding year by year, now counting over 52 National Societies and more than 9,000 individual members from 121 countries. Outstanding scientists and active researchers, Junior Members and Seniors, all work harmoniously to further the understanding and clinical impact of the field and to strengthen the influence of the Academy globally.

There are two categories of individual membership in EAACI:

- **Individual Members**
- **Junior Members**: Individuals aged 35 or under.

Junior Members form a special, particularly dynamic membership group within EAACI with over 4,000 clinicians and scientists, who connect with each other and make a valuable and fresh contribution to the work of the Academy.

EAACI Membership includes a number of benefits for its Members, such as a subscription to the journals “Allergy” and “Pediatric Allergy and Immunology” including supplements, registration fee discounts for EAACI Congresses, Focused Meetings and Allergy Schools, and the possibility to apply for travel grants or join Sections and/or Interest Groups.

“As a clinical allergist I have served on the EAACI Venom Hypersensitivity Interest Group for some considerable time now. Firstly, as a member; then as the secretary and lastly as the Chairperson of the Interest Group. Since June 2011 it has been an honour for me to serve on the EAACI Executive Committee as an Interest Groups Representative. During these years I have personally seen the hard work and effort put in by EAACI, which has resulted in the most important and effective allergy platform and network, stimulating and promoting scientific collaboration between European scientists and clinicians involved in allergy and clinical immunology, as well as disseminating information and awareness of allergic diseases and their treatments among patients and healthcare decision makers.”

Dr. M. Beatrice Bilò
EAACI Newsletter Editor
EAACI Executive Committee
Past EAACI Insect Venom Hypersensitivity Interest Group Chairperson

“Over the last decades EAACI has developed into a forum for the best researchers in the field. At the same time the Academy with its annual congresses and a variety of educational meetings offers a global platform for first class education and postgraduate teaching. For me it has been a great privilege to work for the Academy.”

Prof. Dr Ulrich Wahn
EAACI Past-President
Editor-in-Chief of Pediatric Allergy and Immunology (PAI)
Director of the Paediatric Pneumology and Immunology Charité Clinic, Berlin

European Academy of Allergy and Clinical Immunology
EAACI Membership Benefits

### FEE REDUCTIONS & VOTING RIGHTS

- Reductions on registration fees for EAACI Congresses, Focused Meetings, Schools and EAACI/UEMS Examinations.
- Members of the AAAAI, the ACAAI, the European Respiratory Society and the European Rhinologic Society can apply for dual membership with EAACI at a reduced fee.
- Membership is free for all Junior Members (≤35 years old).
- Members from countries with a GNP of less than USD 10,000 per capita receive a 50% reduction on their membership fee.
- Members receive an EAACI Membership Certificate.
- EAACI European Resident Members can be elected to the Executive Committee and to the Section and Interest Group boards and have full voting rights.

### EDUCATION & RESEARCH

- By joining Sections and Interest Groups, EAACI members can promote the development of allergy research.
- EAACI provides CME credits for all its activities and events. These CME credits are valid in the US and Canada due to a reciprocal agreement between UEMS, AMA and RCPSC.
- Each year EAACI sponsors a number of Clinical and Research Fellowships accessible to all Junior Members.

### RESOURCES

- The EAACI Membership includes a subscription to the journals *Allergy* and *Pediatric Allergy and Immunology*, and online access to *Clinical and Translational Allergy*.
- Members have access to the presentations, slide kits and webcasts presented during its events through www.eaaci.org.
- Members receive a printed copy of the Newsletter.

EAACI Members are eligible for election to the Executive Committee and to the Sections and Interest Groups boards. They have full voting rights.

All EAACI Members receive a Membership Certificate and a Membership Card. Four times a year they receive the EAACI Newsletter with useful and interesting information about the Academy and the field of allergy and clinical immunology.

The Academy offers fellowships and mentorship programmes to Junior Members.

EAACI Membership also embraces National Societies and Patient Organisations interested in allergy and/or clinical immunology, as well as Corporate Societies which wish to support the mission of the Academy.
<table>
<thead>
<tr>
<th>Rank</th>
<th>Country</th>
<th>Members</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Spain</td>
<td>576</td>
</tr>
<tr>
<td>2</td>
<td>Germany</td>
<td>568</td>
</tr>
<tr>
<td>3</td>
<td>Italy</td>
<td>568</td>
</tr>
<tr>
<td>4</td>
<td>United Kingdom</td>
<td>543</td>
</tr>
<tr>
<td>5</td>
<td>Turkey</td>
<td>338</td>
</tr>
<tr>
<td>6</td>
<td>The Netherlands</td>
<td>330</td>
</tr>
<tr>
<td>7</td>
<td>Sweden</td>
<td>298</td>
</tr>
<tr>
<td>8</td>
<td>United States</td>
<td>281</td>
</tr>
<tr>
<td>9</td>
<td>Romania</td>
<td>280</td>
</tr>
<tr>
<td>10</td>
<td>Switzerland</td>
<td>279</td>
</tr>
<tr>
<td>11</td>
<td>Russian Federation</td>
<td>249</td>
</tr>
<tr>
<td>12</td>
<td>Portugal</td>
<td>241</td>
</tr>
<tr>
<td>13</td>
<td>Poland</td>
<td>237</td>
</tr>
<tr>
<td>14</td>
<td>France</td>
<td>236</td>
</tr>
<tr>
<td>15</td>
<td>Greece</td>
<td>230</td>
</tr>
<tr>
<td>16</td>
<td>Austria</td>
<td>220</td>
</tr>
<tr>
<td>17</td>
<td>Belgium</td>
<td>207</td>
</tr>
<tr>
<td>18</td>
<td>Denmark</td>
<td>202</td>
</tr>
<tr>
<td>19</td>
<td>Brazil</td>
<td>170</td>
</tr>
<tr>
<td>20</td>
<td>India</td>
<td>146</td>
</tr>
<tr>
<td>21</td>
<td>Mexico</td>
<td>135</td>
</tr>
<tr>
<td>22</td>
<td>Australia</td>
<td>128</td>
</tr>
<tr>
<td>23</td>
<td>Islamic Republic of Iran</td>
<td>127</td>
</tr>
<tr>
<td>24</td>
<td>Canada</td>
<td>124</td>
</tr>
<tr>
<td>25</td>
<td>China</td>
<td>106</td>
</tr>
<tr>
<td>26</td>
<td>Czech Republic</td>
<td>103</td>
</tr>
<tr>
<td>27</td>
<td>Ukraine</td>
<td>101</td>
</tr>
<tr>
<td>28</td>
<td>Croatia</td>
<td>97</td>
</tr>
<tr>
<td>29</td>
<td>Japan</td>
<td>93</td>
</tr>
<tr>
<td>30</td>
<td>Republic of Korea</td>
<td>90</td>
</tr>
<tr>
<td>31</td>
<td>Georgia</td>
<td>81</td>
</tr>
<tr>
<td>32</td>
<td>Bulgaria</td>
<td>79</td>
</tr>
<tr>
<td>33</td>
<td>Lithuania</td>
<td>78</td>
</tr>
<tr>
<td>34</td>
<td>Norway</td>
<td>78</td>
</tr>
<tr>
<td>35</td>
<td>Slovakia</td>
<td>77</td>
</tr>
<tr>
<td>36</td>
<td>Thailand</td>
<td>77</td>
</tr>
<tr>
<td>37</td>
<td>Egypt</td>
<td>72</td>
</tr>
<tr>
<td>38</td>
<td>Albania</td>
<td>64</td>
</tr>
<tr>
<td>39</td>
<td>Serbia</td>
<td>64</td>
</tr>
<tr>
<td>40</td>
<td>Finland</td>
<td>59</td>
</tr>
<tr>
<td>41</td>
<td>Slovenia</td>
<td>56</td>
</tr>
</tbody>
</table>
EAACI AWARDS

Each year the European Academy of Allergy and Clinical Immunology honours European researchers and clinicians who have contributed significantly to the development of innovative diagnostic and therapeutic strategies for the control and prevention of allergic diseases, to the understanding of their pathophysiology and the strengthening of allergology as a specialty in Europe.

Clemens Von Pirquet Award for Clinical Research
Daniel Bovet Award for Treatment & Prevention
Paul Ehrlich Award for Experimental Research
Charles Blackley Award for Promotion of the Specialty in Europe

<table>
<thead>
<tr>
<th>Year</th>
<th>Clemens Von Pirquet</th>
<th>Daniel Bovet</th>
<th>Paul Ehrlich</th>
<th>Charles Blackley</th>
</tr>
</thead>
<tbody>
<tr>
<td>2005</td>
<td>Dietrich Kraft</td>
<td>Bengt Bjorksten</td>
<td>Barry Kay</td>
<td>Alain de Weck</td>
</tr>
<tr>
<td>2006</td>
<td>William Frankland</td>
<td>Jean Bousquet</td>
<td>Kurt Blaser</td>
<td>SGO Johansson</td>
</tr>
<tr>
<td>2007</td>
<td>Ulrich Müller</td>
<td>Tari Haahtela</td>
<td>Henning Löwenstein</td>
<td>Paul van Cauwenberge</td>
</tr>
<tr>
<td>2008</td>
<td>Andrzej Szczeklik</td>
<td>Ulrich Wahn</td>
<td>Stephen Holgate</td>
<td>Sergio Del Giacco</td>
</tr>
<tr>
<td>2009</td>
<td>Steve Durham</td>
<td>Bengt Bjorksten</td>
<td>Rudi Valenta</td>
<td>Bruenello Wutrich</td>
</tr>
<tr>
<td>2010</td>
<td>Johannes Ring</td>
<td>Hans-Jörgen Malling</td>
<td>Rob Aalberse</td>
<td>Sergio Bonini</td>
</tr>
<tr>
<td>2011</td>
<td>Gabrielle Pauli</td>
<td>Erika von Mutius</td>
<td>Gianne Marone</td>
<td>Anthony J. Frew</td>
</tr>
<tr>
<td>2012</td>
<td>Glenis Scadding</td>
<td>Arne Höst</td>
<td>Werner Pichler</td>
<td>Roy Gerth van Wijk</td>
</tr>
<tr>
<td>2013</td>
<td>Martin K. Church</td>
<td>Claude Molina</td>
<td>Monique Capron</td>
<td>François-Bernard Michel</td>
</tr>
<tr>
<td>2014</td>
<td>Ronald Dahl</td>
<td>Bodo Niggemann</td>
<td>Hannah Gould</td>
<td>Jan Lötvall</td>
</tr>
<tr>
<td>2015</td>
<td>Anne Moneret-Vautrin</td>
<td>Marek Kowalski</td>
<td>Wytske Fokkens</td>
<td>Luis Delgado</td>
</tr>
</tbody>
</table>